Abbott Laboratories ( ABT ) matched Wall Street 's second-quarter earnings estimate Wednesday with sales for a key rheumatoid arthritis drug topping the Street's expectations. The maker of diagnostics, medical devices and drugs reported net income for the June quarter of $1.28 billion, or 83 cents a share, compared with net income of $1.32 billion, or 85 cents a share, in the year-ago quarter. Excluding special items, Abbott reported a 6% increase in earnings to 89 cents a share in the second quarter, in line with the Street's consensus estimate. Second-quarter revenue totaled $7.49 billion, slightly below the consensus analyst forecast of $7.55 billion. Abbott reported revenue of $7.31 billion in the year-ago quarter. Of most interest to investors, sales of Abbott's rheumatoid arthritis drug Humira rose 33% to $1.3 billion in the June quarter, adjusted for negative currency effects.